Fusion Pharmaceuticals Inc.
↗Hamilton, Ontario, Canada
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that specializes in developing targeted alpha-particle radiotherapies (targeted alpha therapies or TATs) for the treatment of cancer. The company harnesses a potent and precise cell-killing strategy by connecting alpha particle-emitting isotopes (such as actinium-225) to cancer-seeking molecules using its proprietary Fast-Clear™ linker technology, which selectively delivers alpha-emitting payloads to tumors while improving clearance from healthy tissues. As a spinout of the Centre for Probe Development and Commercialization (CPDC) at McMaster University, Fusion brings pioneering expertise in radiopharmaceutical research, development, manufacturing, and GMP production capabilities. The company was acquired by AstraZeneca in June 2024 for approximately $2.4 billion.
CLASSIFICATION
SIZE & FINANCIALS
Employees:101-200
Founded:2014
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Pre-IPO
Total Raised:$171M
Investors:Johnson & Johnson Innovation (JJDC), HealthCap, TPG Biotech, Genesys Capital, FACIT
STOCK
Exchange:NASDAQ
Ticker:FUSN
PIPELINE
Stage:Phase 1|Phase 2|Phase 3
Lead Drug Stage:Phase 2
Modalities:Radiopharmaceuticals, Targeted Alpha Therapies (TATs), Radioconjugates, Radioimmunoconjugates, Small molecule radiopharmaceuticals
Active Trials:3
Trial Phases:Phase 1: 2 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:AstraZeneca
Acquired By:AstraZeneca (2024-06-04)
Key Partnerships:AstraZeneca: Parent company post-acquisition (June 2024). Prior collaboration for developing novel targeted alpha therapies and combination programs with AstraZeneca's DNA Damage Response Inhibitors and immuno-oncology agents., Merck: Clinical collaboration to evaluate FPI-1434 in combination with KEYTRUDA (pembrolizumab) in patients with solid tumors expressing IGF-1R, Pepscan: Research collaboration for developing peptide-based radiopharmaceuticals, McMaster University/CPDC: Exclusive license agreement for radiopharmaceutical technology and patents; 15-year lease for manufacturing facility at McMaster Innovation Park
COMPETITION
Position:Challenger
Competitors:Novartis (Lutathera, Pluvicto - market leaders), Eli Lilly (Point Biopharma acquisition - $1.4B), Bristol Myers Squibb (RayzeBio acquisition - $4.1B), RadioMedix, Primo Biotechnology, Abdera Therapeutics, Precirix
LEADERSHIP
Key Executives:
John Valliant, PhD - Founder and Chief Executive Officer
Christopher Leamon - Chief Scientific Officer
Eric S. Hoffman - Senior Vice President, Business Development
Mohit Rawat - President & Chief Business Officer
John J. Crowley - Chief Financial Officer
Scientific Founders:John Valliant, PhD (Founder)
Board Members:Barbara Duncan (Chairperson), John Valliant (Board Member), Jeremy Bender, PhD, MBA (Board Member), Teresa Bitetti, MBA (Board Member), David Meek (Board Member), Donald A. Bergstrom, MD, PhD (Board Member), Steven Gannon (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Fusion Pharmaceuticals Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.